Logotype for Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) investor relations material

Regeneron Pharmaceuticals Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Regeneron Pharmaceuticals Inc
Q3 2025 earnings summary28 Oct, 2025

Executive summary

  • Q3 2025 revenues were $3.75B, with GAAP net income up 9% to $1.46B and non-GAAP EPS at $11.83, driven by strong Dupixent, EYLEA HD, and Libtayo performance, despite a sharp EYLEA U.S. decline from biosimilar competition.

  • Four blockbuster products, a robust pipeline of ~45 candidates, and a strong financial position support continued growth.

  • Strategic focus on R&D, capital returns, and business development, with over $5B invested in R&D in 2025+ and $2.8B in share repurchases YTD.

  • Cash flow from operations for the nine months ended September 30, 2025, was $3.8B, up 21% year-over-year, supporting ongoing share repurchases and dividends.

  • Significant regulatory approvals and pipeline progress, including positive Phase 3 results in myasthenia gravis, FOP, and allergy programs.

Financial highlights

  • Q3 2025 total revenues reached $3.75B; net income was $1.46B (+9% YoY); diluted GAAP EPS: $13.62 (+18%); non-GAAP EPS: $11.83 (-5%).

  • Dupixent global net sales (Sanofi) up 27% YoY to $4.86B; Regeneron's share of profits: $1.46B (+34%).

  • EYLEA HD U.S. Q3 sales: $431M (+10%); EYLEA U.S. Q3 sales: $681M (-41%).

  • Libtayo Q3 2025 worldwide net sales were $365M (+26% YoY), surpassing $1B YTD.

  • Gross margin on net product sales: 82% in Q3 2025 (down from 87% in Q3 2024).

Outlook and guidance

  • Full reimbursement of Sanofi development balance expected by end of Q3 2026, driving significant growth in collaboration revenue.

  • Management expects continued pressure on EYLEA sales due to biosimilar launches, but EYLEA HD and Dupixent growth to partially offset declines.

  • Full-year 2025 guidance: GAAP R&D $5.68–$5.75B, non-GAAP R&D $5.10–$5.20B, GAAP SG&A $2.81–$2.94B, non-GAAP SG&A $2.40–$2.45B.

  • Capital expenditures for 2025 guided at $1.0–$1.05B.

  • Key 2025 milestones include regulatory submissions, pivotal data readouts, and expansion into obesity and genetic medicines.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Regeneron Pharmaceuticals earnings date

Logotype for Regeneron Pharmaceuticals Inc
Q4 20253 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Regeneron Pharmaceuticals earnings date

Logotype for Regeneron Pharmaceuticals Inc
Q4 20253 Feb, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Regeneron Pharmaceuticals Inc is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company has a pipeline of product candidates comprising multiple therapeutic candidates in Phase I and Phase II clinical studies for the treatment of cancer, wet age-related macular degeneration and diabetic macular edema, atopic dermatitis, asthma, pain, and monoclonal antibodies.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage